Soligenix

Soligenix CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Soligenix (SNGX) as of Oct 19, 2026 is -0.06 %.

CapEx/OCF

-0.06 %

Last updated:

CapEx to Operating Cash Flow Ratio of Soligenix is 2025 -0.06 % . CapEx to Operating Cash Flow Ratio of Soligenix was 2024 0.00 . It decreases by % lower compared to the previous year.

The Soligenix CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-0.03 USD
Jan 1, 2019
-0.40 USD
Jan 1, 2020
-0.06 USD
Jan 1, 2021
-0.10 USD
Jan 1, 2022
-0.10 USD
Jan 1, 2023
-0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
-0.06 USD
The Soligenix CapEx/OCF history
YEARCapEx/OCFYoY
-0.06 %—
0.00-100.00%
-0.00-99.99%
-0.10 %+2.92%
-0.10 %+60.94%
-0.06 %-84.49%
-0.40 %+1,413.93%
-0.03 %-93.43%
-0.40 %+181.65%
-0.14 %-64.98%
-0.41 %-80.10%
-2.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

CapEx to Operating Cash Flow Ratio of Soligenix is -0.06 % in 2025.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Soligenix since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Soligenix with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Soligenix

All Key Metrics — Soligenix